Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a regenerative medicine company operating in a single segment. The company's diverse product portfolio has a strong foothold in the skin substitute segment of the advanced wound care market. However, CMS reimbursement changes have impacted the industry, leading to a decline in revenue in 2026. Despite this challenge, Organogenesis has a significant potential for growth in the long term due to the increasing demand for advanced wound care technologies and the company's unique product offerings. As a result, the company's stock is currently trading at a discounted price compared to its peers, presenting a good opportunity for investment.

Bears say

Organogenesis Holdings is facing numerous challenges in its market segment and business model which are negatively impacting its financial performance. The company has a pureplay exposure to reimbursement, which is a major concern in the regenerative medicine market. The recent reimbursement cuts have resulted in a seismic decline in the end market for the company, with an estimated 60-90% reduction in demand. This has been further exacerbated by a wastage ruling that is disproportionately impacting one of Organogenesis's key products, Apligraf, leading to a negative economic incentive for its use. These factors have led to a significant decline in the company's revenue and profitability, and while there is potential for growth in the long term, the uncertainty and ongoing shifts in the market make it difficult to predict when this will be realized. Additionally, the company's potential new product, ReNu, represents a binary outcome with FDA decision and would only contribute to revenue and profitability in 2028 at the earliest.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.